Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Period	PE Ratio
2021-12-31	-0.90
2022-12-31	-1.46
2023-12-31	-1.80
2024-12-31	-2.11

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SERA	$2.09	+0.00%	0.02M
3
4
5

Sera Prognostics Inc. (SERA) PE Ratio

PE Ratio Data

Get Sera Prognostics Inc. Data in Excel

More SERA Financial Data